Cardiovascular Research with a patient oriented focus

Cardiovascular Research with a patient oriented focusCardiovascular Research with a patient oriented focusCardiovascular Research with a patient oriented focus

Cardiovascular Research with a patient oriented focus

Cardiovascular Research with a patient oriented focusCardiovascular Research with a patient oriented focusCardiovascular Research with a patient oriented focus
  • Home
  • Podcasts
  • Research
  • Documents
  • About Us
  • Contact Us
  • FuturePulse Apple Podcast
  • PatientPulse ApplePodcast
  • EVOLVE-MI
  • PREVAIL
  • SURMOUNT-MMO
  • OCEAN(a) Lp(a)
  • More
    • Home
    • Podcasts
    • Research
    • Documents
    • About Us
    • Contact Us
    • FuturePulse Apple Podcast
    • PatientPulse ApplePodcast
    • EVOLVE-MI
    • PREVAIL
    • SURMOUNT-MMO
    • OCEAN(a) Lp(a)

  • Home
  • Podcasts
  • Research
  • Documents
  • About Us
  • Contact Us
  • FuturePulse Apple Podcast
  • PatientPulse ApplePodcast
  • EVOLVE-MI
  • PREVAIL
  • SURMOUNT-MMO
  • OCEAN(a) Lp(a)

Current research activity

Weight Loss / Cardiovascular Risk Reduction

 SURMOUNT-MMO GLP1-RA for weight loss in patients without diabetes and increased cardiovascular risk.  Enrollment closed.


 TRIUMPH-OUTCOMES GLP "triple agonist" trial for diabetetics and non-diabetics for cardiovascular risk and weight reduction.  Open for enrollment


 AFRICAN AMERICAN HEART STUDY registry run by Asscoiatation of Black Cardiologists studying Lp(a) and CV outcomes in the AA community. Enrollment closed.


Coronary Artery Disease/Dyslipidemia Trials

 ACCLAIM-Lp(a) (Lilly) Phase III •Lepodisiran (siRNA to inhibit formation of Lp(a)) vs. Placebo on top of maximal therapy; examining outcomes patients with CAD and in high risk  primary prevention patients .  Enrolling now.


 CORALReef (Merck) Phase III •Oral PCSK(9i MK0616  vs standard of care for CAD and high risk patients.  Enrollment open.


 Evolve-MI (Amgen) Phase IV • Evolucumab + statin vs standard of care early after MI (STEMI/ACS NSTEMI).  Enrollment closed.


 Librexia-ACS  Phase III • Milvexian  (FXIa inhibitor) vs. apixaban for patients with STEMI/Non-STEMI ACS.


 PREVAIL (New Amsterdam Pharma) Phase III • Obicetrapib (CETP inhibitor) vs placebo PO Daily for patients with ASCVD and LDL chol >70 .  Enrollemtn closed.


 PREVENT (Novartis) Phase III •Phase III • Inclisiran (siRNA, PCSK9 inhibitor) vs. Placebo on top of maximal therapy; examining outcomes in high risk  patients, Enrollment closed.


 Oceans(a) (Amgen) Phase III • Olparsiran vs standard of care early after treatment of Lipoprotein a (Lp(a)) in patients with h/o MI or high risk patients after PCI.  Double blind placebo controlled study.  Enrollment closed.


 ORION-4 (Novartis)- Phase III • Inclisiran (siRNA, PCSK9 inhibitor) vs. Placebo; examining outcomes in subjects with heart attack or stroke .  Enrollment closed.


 VICTORION-INITIATE (Novartis)- Phase III • (*closed/completed*) Inclisiran (siRNA, PCSK9 inhibitor) vs. Usual Care; assessing an “inclisiran-first” strategy in an ASCVD population.  Enrollment closed.


Arrhythmia Trials

 Librexia-AF  Phase III • Milvexian  (FXIa inhibitor) vs. apixaban for patients with atrial fibrillation.   Enrolling now.


 AZALEA (Anthos/TIMI)- Phase III • Abelacimab (subcutaneous monoclonal antibody) vs. Rivaroxaban; assessing the bleeding profile of abelacimab in patients with AF with moderate-to-high risk of stroke o Paroxysmal Supraventricular Tachycardia.  CLOSED EARLY DUE TO EFFICACY!


 LILAC (Anthos/TIMI)- Phase III (*no longer enrolling*) • Abelacimab (subcutaneous monoclonal antibody) in patients who cannot tolerate anti-coagulation.  Enrolling now.

Aortic Valve Regurgitation & Stenosis Trials

 Expand TAVR II (Medtronic) • Evolut™ PRO and Evolut™ PRO+ Device in patients with moderate AS and Class II-III heart failure.


 Optimize PRO (Medtronic) • (*no longer enrolling*) Evolut™ PRO and Evolut™ PRO+ Device Trial examining valve performance & procedural outcomes associated with an “optimized” TAVR (transcatheter aortic valve replacement) care pathway & post-TAVR conduction disturbance pathway


Mitral Regurgitation & Stenosis Trials

 EXPAND G4 (Abbott) (*no longer enrolling*) • MitraClip device trial evaluating outcomes & characterizing trends in patient selection 


Heart Failure Trials

 HERMES (Novo Nordisk)- Phase III • Ziltivekimab IL-6 blocking agent  vs. Placebo in  patients with chronic heart failure with preserved ejection fraction  and elevated hs-CRP


 GPID SUMMIT (Eli Lilly)- Phase III • Tirzepatide (GIP & GLP-1 agonist) vs. Placebo in obese patients with chronic heart failure with preserved ejection fraction .  Closed for enrollemtn.  Top line results demonstrated  efficacy.


Copyright © 2022 FuturePulse Thomas Nero MD- All Rights Reserved.

Powered by GoDaddy